Ask AI
ProCE Banner Activity

ExpressPoints: HER2-Positive Breast Cancer: A Guide Through an Evolving Treatment Landscape

Slideset

Download this short summary slideset on current optimal treatment for patients with HER2-positive breast cancer.

Released: February 09, 2021

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Genentech, a member of the Roche Group

Puma Biotechnology, Inc.

Faculty Disclosure

Primary Author

Jame Abraham, MD, FACP

Enterprise Chairman, Department of Hematology and Medical Oncology
Professor of Medicine
Lerner College of Medicine
Cancer Institute, Cleveland Clinic
Cleveland, Ohio

Jame Abraham, MD, FACP, has no relevant financial relationships to disclose.

Hope S. Rugo, MD

Clinical Professor of Medicine
UCSF Comprehensive Cancer Center
University of California, San Francisco
San Francisco, California

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Artios, Arvinas, AstraZeneca, Atkis Oncology, Avenzo, Bayer, BeOne, Bicycle, BioNTech, Boehringer Ingelheim, Boundless Bio, Bristol Myers Squibb/SystImmune, Celcuity, Circle, Cullinan Oncology, Daiichi Sankyo, Denali, Eisai, Genentech/Roche, Gilead, Jazz, Johnson & Johnson/Ambrx, Launch, Lilly, Menarini/Stemline, Merck, Mersana, Novartis, Olema, Pfizer/SeaGen, Reveal Genomics, Samsung Bioepis, Summit, Tempus, Zuellig; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString, Novartis, OncoPep, Pfizer/SeaGen.